Comparison · NCT02667236-e2b1b78b
A-101 Solution vs Vehicle Solution: Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. A-101 Solution vs Vehicle Solution: Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment. Trial comparisons, record NCT02667236-e2b1b78b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02667236-e2b1b78b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0404 | 0.0214 | 0.0749 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0166 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0404 | 0.0151 | 0.0749 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on A-101 Solution than on Vehicle Solution | 24.8 | 13.3 | 66.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | A-101 Solution | A-101 Solution 40% applied topically~A-101 Solution: Active Drug | 9 | 223 | OG000 |
| Group 2 | Vehicle Solution | Vehicle Solution applied topically~Vehicle Solution: Placebo | 0 | 227 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment
- Description
Proportion of subjects for whom all target lesions were judged to be clear on the Physician Lesion Assessment Scale (PLA=0) at Visit 8. The PLA Scale is a 4 point scale used by the investigator to assess each subject's target SK Lesion.
- Time frame
- Day 106 of the study
- Population
- ITT Population; all randomized subjects
Source ClinicalTrials.gov
Trial
- Title
- A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
- NCT number
- NCT02667236
- Phases
- PHASE3
- Conditions
- Seborrheic Keratosis
- Interventions
- A-101 Solution, Vehicle Solution
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Results first posted
- 2017-11-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02667236?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02667236-e2b1b78b